Other studies represented that in the general population, adults with a higher IGF1/IGFBP3 ratio have a lower NAFLD risk (40), and NAFLD patients have a lower IGF1/IGFBP3 ratio (41). This evidence concerns the gene IGF1 and metabolic dysfunction-associated steatotic liver disease.